GB9526733D0
(en)
*
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
US7153943B2
(en)
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US7495087B2
(en)
|
1997-07-14 |
2009-02-24 |
Bolder Biotechnology, Inc. |
Cysteine muteins in the C-D loop of human interleukin-11
|
JP2001510033A
(ja)
|
1997-07-14 |
2001-07-31 |
ボルダー バイオテクノロジー, インコーポレイテッド |
成長ホルモンおよび関連タンパク質の誘導体
|
US20080076706A1
(en)
*
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
AU762621B2
(en)
|
1998-04-28 |
2003-07-03 |
Merck Serono Sa |
Polyol-IFN-beta conjugates
|
WO2000023472A2
(en)
|
1998-10-16 |
2000-04-27 |
Biogen, Inc. |
Interferon-beta fusion proteins and uses
|
CN101062419B
(zh)
|
1998-10-16 |
2016-06-29 |
生物基因Ma公司 |
干扰素-β-1a的聚合物缀合物及其使用
|
IL144259A0
(en)
*
|
1999-01-14 |
2002-05-23 |
Bolder Biotechnology Inc |
Methods for making proteins containing free cysteine residues
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US6531122B1
(en)
|
1999-08-27 |
2003-03-11 |
Maxygen Aps |
Interferon-β variants and conjugates
|
US7431921B2
(en)
|
2000-04-14 |
2008-10-07 |
Maxygen Aps |
Interferon beta-like molecules
|
US7144574B2
(en)
|
1999-08-27 |
2006-12-05 |
Maxygen Aps |
Interferon β variants and conjugates
|
IL147581A0
(en)
*
|
1999-08-27 |
2002-08-14 |
Maxygen Aps |
New interferon beta-like molecules
|
AU782635B2
(en)
*
|
1999-11-12 |
2005-08-18 |
Maxygen Holdings Ltd. |
Interferon gamma conjugates
|
JP2003514552A
(ja)
*
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
CN1309423C
(zh)
*
|
1999-11-12 |
2007-04-11 |
马克西根控股公司 |
干扰素γ偶联物
|
WO2001036001A2
(en)
*
|
1999-11-12 |
2001-05-25 |
Maxygen Holdings Ltd |
Interferon gamma conjugates
|
US6831158B2
(en)
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6555660B2
(en)
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
PT1257295E
(pt)
|
2000-02-11 |
2009-07-16 |
Bayer Healthcare Llc |
Moléculas de tipo factor vii ou viia
|
EP1257574A1
(en)
*
|
2000-02-11 |
2002-11-20 |
Maxygen Aps |
Improved interleukin 10
|
US6602498B2
(en)
|
2000-02-22 |
2003-08-05 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
JP4873818B2
(ja)
*
|
2000-05-16 |
2012-02-08 |
ボルダー バイオテクノロジー, インコーポレイテッド |
遊離システイン残基を含有するタンパク質をリフォールディングする方法
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
KR20030046411A
(ko)
*
|
2000-09-08 |
2003-06-12 |
그리폰 테라퓨틱스, 인코포레이티드 |
'위'-천연 화학적 라이게이션
|
ATE421535T1
(de)
*
|
2000-10-16 |
2009-02-15 |
Chugai Pharmaceutical Co Ltd |
Peg-modifiziertes erythropoietin
|
US6673580B2
(en)
*
|
2000-10-27 |
2004-01-06 |
Genentech, Inc. |
Identification and modification of immunodominant epitopes in polypeptides
|
AU2002212107A1
(en)
*
|
2000-11-02 |
2002-05-15 |
Maxygen Aps |
New multimeric interferon beta polypeptides
|
CA2430934C
(en)
|
2000-12-01 |
2011-06-21 |
Takeda Chemical Industries, Ltd. |
A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
|
WO2002055532A2
(en)
*
|
2001-01-11 |
2002-07-18 |
Maxygen Aps |
Variant growth hormone molecules conjugated with macromolecular compounds
|
US7442370B2
(en)
|
2001-02-01 |
2008-10-28 |
Biogen Idec Ma Inc. |
Polymer conjugates of mutated neublastin
|
PL362396A1
(en)
*
|
2001-02-06 |
2004-11-02 |
Merck Patent Gmbh |
Modified erythropoietin (epo) with reduced immunogenicity
|
CZ20032526A3
(cs)
*
|
2001-02-27 |
2003-12-17 |
Maxygen Aps |
Nové molekuly podobné interferonu beta
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
US7038015B2
(en)
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
JP4123856B2
(ja)
|
2001-07-31 |
2008-07-23 |
日油株式会社 |
生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
|
CA2461292A1
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
AU2002356990A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Pharmacia Corporation |
Chemically-modified human growth hormone conjugates
|
KR100467750B1
(ko)
*
|
2001-11-29 |
2005-01-24 |
씨제이 주식회사 |
생체내 에리스로포이에틴 활성이 증진된 융합단백질
|
US7247609B2
(en)
|
2001-12-18 |
2007-07-24 |
Universitat Zurich |
Growth factor modified protein matrices for tissue engineering
|
WO2003055526A2
(en)
*
|
2001-12-21 |
2003-07-10 |
Maxygen Aps |
Erythropoietin conjugates
|
US20080167238A1
(en)
*
|
2001-12-21 |
2008-07-10 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
JPWO2003064462A1
(ja)
*
|
2002-02-01 |
2005-05-26 |
中外製薬株式会社 |
Peg結合pth又はpeg結合pth誘導体
|
KR101121593B1
(ko)
|
2002-04-30 |
2012-04-12 |
맥시겐 홀딩스 엘티디 |
인자 ⅶ 또는 ⅶ에이 폴리펩티드 변이체
|
JP4574350B2
(ja)
|
2002-06-24 |
2010-11-04 |
ジェネンテック, インコーポレイテッド |
Apo−2リガンド/trail変異体とその使用法
|
EP1539814A2
(en)
*
|
2002-07-03 |
2005-06-15 |
Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited |
Full-length interferon gamma polypeptide variants
|
EP1391513A1
(en)
|
2002-08-08 |
2004-02-25 |
Cytheris |
IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
|
WO2004014938A2
(en)
*
|
2002-08-09 |
2004-02-19 |
Xencor |
Thrombopoiesis-stimulating proteins having reduced immunogenicity
|
WO2004020468A2
(en)
*
|
2002-08-28 |
2004-03-11 |
Maxygen Aps |
Interferon beta-like molecules for treatment of cancer
|
CA2498319A1
(en)
*
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
WO2004044006A1
(en)
*
|
2002-11-14 |
2004-05-27 |
Maxygen, Inc. |
Conjugates of interleukin-10 and polymers
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
PL396711A1
(pl)
*
|
2002-12-26 |
2011-12-19 |
Mountain View Pharmaceuticals, Inc. |
Koniugaty polimerów z cytokinami, chemokinami, czynnikami wzrostu, hormonami polipeptydowymi i ich antagonistami, kompozycja farmaceutyczna i sposób zapobiegania, diagnozowania lub leczenia
|
NZ541124A
(en)
|
2002-12-26 |
2008-08-29 |
Mountain View Pharmaceuticals |
Polymer conjugates of interferon-beta with enhanced biological potency
|
KR101025143B1
(ko)
|
2002-12-31 |
2011-04-01 |
넥타르 테라퓨틱스 |
가수분해상으로 안정한 말레이미드-종결 중합체
|
EP1578841B2
(en)
|
2002-12-31 |
2016-10-12 |
Nektar Therapeutics AL, Corporation |
Maleamic acid polymer derivatives and their bioconjugates
|
US7432331B2
(en)
|
2002-12-31 |
2008-10-07 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
EP2301960A3
(en)
*
|
2003-01-31 |
2011-08-03 |
Biogen Idec MA Inc. |
Polymer conjugates of mutated neublastin
|
JP4847856B2
(ja)
|
2003-03-20 |
2011-12-28 |
バイエル ヘルスケア エルエルシー |
FVIIおよびFVIIaの変種
|
US20070184519A1
(en)
*
|
2003-04-02 |
2007-08-09 |
Shabnam Tangri |
Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
|
WO2004091517A2
(en)
|
2003-04-15 |
2004-10-28 |
Smithkline Beecham Corporation |
Conjugates comprising human il-18 and substitution mutants thereof
|
WO2004099245A1
(de)
*
|
2003-05-05 |
2004-11-18 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Stabilisiertes interferon-ϝ
|
EP1644504B8
(en)
|
2003-06-19 |
2010-06-02 |
Bayer HealthCare LLC |
Factor vii or viia gla domain variants
|
US7785580B2
(en)
|
2003-08-29 |
2010-08-31 |
Aerovance, Inc. |
Modified IL-4 mutein receptor antagonists
|
US7404957B2
(en)
*
|
2003-08-29 |
2008-07-29 |
Aerovance, Inc. |
Modified IL-4 mutein receptor antagonists
|
US20060228331A1
(en)
|
2003-10-10 |
2006-10-12 |
Novo Nordisk A/S |
IL-21 Derivatives and variants
|
CA2542179A1
(en)
*
|
2003-10-10 |
2005-04-21 |
Novo Nordisk A/S |
Il-21 derivatives
|
WO2005056636A2
(en)
|
2003-12-03 |
2005-06-23 |
Nektar Therapeutics Al, Corporation |
Method of preparing maleimide functionalized polymers
|
AU2004311796A1
(en)
*
|
2003-12-31 |
2005-07-21 |
Centocor, Inc. |
Novel recombinant proteins with N-terminal free thiol
|
PT1706428E
(pt)
|
2004-01-22 |
2009-12-29 |
Merck Patent Gmbh |
Anticorpos anticancerígenos com fixação de complemento reduzida
|
MXPA06008506A
(es)
*
|
2004-02-02 |
2007-01-30 |
Ambrx Inc |
Polipeptidos de hormona de crecimiento humana modificada y sus usos.
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
AU2005245918A1
(en)
|
2004-05-19 |
2005-12-01 |
F. Hoffmann-La Roche Ag |
Interferon-alpha polypeptides and conjugates
|
AU2005265163B2
(en)
|
2004-06-18 |
2009-10-01 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
CA2573262C
(en)
*
|
2004-07-16 |
2015-02-10 |
Nektar Therapeutics Al, Corporation |
Conjugates of a gm-csf moiety and a polymer
|
WO2006023782A2
(en)
|
2004-08-19 |
2006-03-02 |
Biogen Ideca Ma Inc. |
Refolding transforming growth factor beta family proteins
|
AU2005278903A1
(en)
*
|
2004-08-31 |
2006-03-09 |
Pharmacia & Upjohn Company Llc |
Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
KR101904630B1
(ko)
|
2004-11-12 |
2018-10-04 |
바이엘 헬스케어 엘엘씨 |
Fviii의 부위 지향 변형
|
JP5425398B2
(ja)
*
|
2004-12-22 |
2014-02-26 |
アンブレツクス・インコーポレイテツド |
非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
|
EP1836298B1
(en)
|
2004-12-22 |
2012-01-18 |
Ambrx, Inc. |
COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
|
NZ555206A
(en)
|
2004-12-22 |
2010-09-30 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
MX2007007580A
(es)
|
2004-12-22 |
2007-12-11 |
Ambrx Inc |
Hormona del crecimiento humana modificada.
|
US7816320B2
(en)
|
2004-12-22 |
2010-10-19 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
|
US7714114B2
(en)
|
2005-02-16 |
2010-05-11 |
Nektar Therapeutics |
Conjugates of an EPO moiety and a polymer
|
AU2006299901A1
(en)
|
2005-05-18 |
2007-04-19 |
Maxygen, Inc. |
Evolved interferon-alpha polypeptides
|
CA2607844C
(en)
|
2005-06-01 |
2012-07-10 |
Maxygen Holdings Ltd. |
Pegylated g-csf polypeptides and methods of producing same
|
JP2008541769A
(ja)
*
|
2005-06-03 |
2008-11-27 |
アンブレツクス・インコーポレイテツド |
改善されたヒトインターフェロン分子及びそれらの使用
|
KR100694994B1
(ko)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
사람 과립구 콜로니 형성인자 동종체
|
CN101304758B
(zh)
|
2005-06-29 |
2013-08-21 |
维兹曼科学研究所耶达研究与发展有限公司 |
重组干扰素α2(IFNα2)突变体
|
KR100735784B1
(ko)
*
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
EP1951890A4
(en)
|
2005-11-16 |
2009-06-24 |
Ambrx Inc |
PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
|
CN101448512B
(zh)
*
|
2005-12-14 |
2015-11-25 |
Ambrx公司 |
含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
|
EP1978994B1
(en)
*
|
2005-12-22 |
2012-02-01 |
Janssen Biotech, Inc. |
Bmp-7 variant compositions, methods and uses
|
US7659250B2
(en)
|
2005-12-22 |
2010-02-09 |
Centocor, Inc. |
BMP-7 variant compositions, methods and uses
|
ES2365046T3
(es)
|
2005-12-30 |
2011-09-21 |
Merck Patent Gmbh |
Anticuerpos anti-cd19 con inmunogenicidad reducida.
|
PL1966238T3
(pl)
|
2005-12-30 |
2012-09-28 |
Merck Patent Gmbh |
Warianty interleukiny-12p40 o polepszonej stabilności
|
EP1986694B1
(en)
*
|
2006-02-14 |
2015-06-10 |
Novo Nordisk Health Care AG |
Coupling of polypeptides at the c-terminus
|
TWI501774B
(zh)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
神經性病症之治療
|
US20080003202A1
(en)
*
|
2006-03-28 |
2008-01-03 |
Thierry Guyon |
Modified interferon-beta (IFN-beta) polypeptides
|
US20100016550A1
(en)
|
2006-05-26 |
2010-01-21 |
Zheng Xin Dong |
Methods for Site-Specific Pegylation
|
WO2008014054A2
(en)
*
|
2006-07-27 |
2008-01-31 |
Centocor, Inc. |
Bmp-7 variant compositions, methods and uses
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
|
ES2457527T3
(es)
|
2006-09-08 |
2014-04-28 |
Ambrx, Inc. |
ARNt Supresor hibrido en células de vertebrados
|
SG174788A1
(en)
|
2006-09-08 |
2011-10-28 |
Ambrx Inc |
Suppressor trna transcription in vertebrate cells
|
CA2666426A1
(en)
|
2006-10-26 |
2008-05-02 |
Novo Nordisk A/S |
Il-21 variants
|
WO2008065372A2
(en)
*
|
2006-11-28 |
2008-06-05 |
Nautilus Biotech, S.A. |
Modified erythropoietin polypeptides and uses thereof for treatment
|
US8617531B2
(en)
|
2006-12-14 |
2013-12-31 |
Bolder Biotechnology, Inc. |
Methods of making proteins and peptides containing a single free cysteine
|
PE20090722A1
(es)
*
|
2007-02-02 |
2009-07-13 |
Amgen Inc |
Hepcidina, antagonistas de la hepcidina y metodos de uso
|
PL2068909T3
(pl)
|
2007-03-30 |
2012-09-28 |
Ambrx Inc |
Modyfikowane polipeptydy fgf-21 i ich zastosowanie
|
WO2008137574A1
(en)
|
2007-05-01 |
2008-11-13 |
Biogen Idec Ma Inc. |
Compositions and methods for increasing vascularization
|
CA2685596A1
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
US8383114B2
(en)
*
|
2007-09-27 |
2013-02-26 |
Amgen Inc. |
Pharmaceutical formulations
|
WO2009064838A1
(en)
|
2007-11-15 |
2009-05-22 |
Amgen, Inc. |
Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
|
KR101656107B1
(ko)
|
2007-11-20 |
2016-09-08 |
암브룩스, 인코포레이티드 |
변형된 인슐린 폴리펩티드 및 이의 용도
|
CA2707979A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Biovectra Inc. |
Polypeptides modified by protein trans-splicing technology
|
EP2227263A2
(en)
|
2007-12-28 |
2010-09-15 |
Kuros Biosurgery AG |
Pdgf fusion proteins incorporated into fibrin foams
|
JP5514736B2
(ja)
|
2008-01-11 |
2014-06-04 |
セリナ・セラピユーテイツクス・インコーポレーテツド |
ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
|
US8101706B2
(en)
|
2008-01-11 |
2012-01-24 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
CA2711826C
(en)
|
2008-01-25 |
2018-02-27 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
EP3103880A1
(en)
|
2008-02-08 |
2016-12-14 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
CN101525381B
(zh)
*
|
2008-03-04 |
2012-04-18 |
北京百川飞虹生物科技有限公司 |
一种重组复合干扰素及其表达载体的构建和表达
|
JP2011519279A
(ja)
|
2008-05-01 |
2011-07-07 |
アムジエン・インコーポレーテツド |
抗ヘプシジン抗体及び使用の方法
|
US20110171168A1
(en)
*
|
2008-05-13 |
2011-07-14 |
Nora Therapeutics, Inc. |
Human g-csf analogs and methods of making and using thereof
|
WO2009139784A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Nora Therapeutics, Inc. |
Human g-csf analogs and methods of making and using thereof
|
MX2011000859A
(es)
|
2008-07-23 |
2011-02-24 |
Ambrx Inc |
Polipeptidos g-csf bovinos modificados y sus usos.
|
CN102112157B
(zh)
*
|
2008-08-06 |
2013-05-29 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内效能的缀合蛋白
|
TR201802361T4
(tr)
|
2008-09-26 |
2018-03-21 |
Ambrx Inc |
Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
|
MX346001B
(es)
|
2008-09-26 |
2017-03-01 |
Ambrx Inc |
Polipeptidos de eritropoyetina animal modificados y sus usos.
|
US8318167B2
(en)
|
2008-11-13 |
2012-11-27 |
The General Hospital Corporation |
Methods and compositions for regulating iron homeostasis by modulation of BMP-6
|
US20100221236A1
(en)
*
|
2008-12-05 |
2010-09-02 |
Satish Singh |
Mutants of Staphylokinase Carrying Amino and Carboxy-Terminal Extensions for Polyethylene Glycol Conjugation
|
MX2011007736A
(es)
*
|
2009-01-22 |
2011-09-06 |
Novo Nordisk Healthcare Ag |
Compuestos de hormona del crecimiento estables.
|
US8940501B2
(en)
|
2009-01-30 |
2015-01-27 |
Whitehead Institute For Biomedical Research |
Methods for ligation and uses thereof
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
WO2010121766A1
(en)
|
2009-04-22 |
2010-10-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
EP2427204B1
(en)
|
2009-05-06 |
2017-04-05 |
Janssen Biotech, Inc. |
Melanocortin receptor binding conjugates
|
WO2011015649A1
(en)
*
|
2009-08-06 |
2011-02-10 |
Novo Nordisk Health Care Ag |
Growth hormones with prolonged in-vivo efficacy
|
CA2775287A1
(en)
*
|
2009-09-25 |
2011-03-31 |
Vybion, Inc. |
Polypeptide modification
|
AU2010310457B2
(en)
|
2009-10-23 |
2015-07-02 |
Amgen Inc. |
Vial adapter and system
|
EP3778917A3
(en)
|
2009-12-04 |
2021-06-09 |
F. Hoffmann-La Roche AG |
Multispecific antibodies, antibody analogs, compositions, and methods
|
BR112012015461A2
(pt)
|
2009-12-21 |
2017-01-10 |
Ambrx Inc |
polipeptídeos de somatotropina boviina modificados e seus usos
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
JP5980689B2
(ja)
|
2010-01-22 |
2016-08-31 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
安定な成長ホルモン化合物
|
TWI508737B
(zh)
*
|
2010-01-22 |
2015-11-21 |
諾佛 儂迪克股份有限公司 |
具有延長的活體內功效的生長激素
|
WO2011133948A2
(en)
|
2010-04-22 |
2011-10-27 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
CN103025369B
(zh)
|
2010-06-07 |
2016-07-06 |
安姆根有限公司 |
药物递送装置
|
EP2595661A1
(en)
*
|
2010-07-22 |
2013-05-29 |
Novo Nordisk Health Care AG |
Growth hormone conjugates
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
MY162837A
(en)
|
2010-08-17 |
2017-07-31 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
EP2663647A4
(en)
|
2011-01-14 |
2015-08-19 |
Redwood Bioscience Inc |
POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
|
CA2824515C
(en)
|
2011-01-18 |
2022-09-13 |
Bioniz, Llc |
Compositions and methods for modulating gamma-c-cytokine activity
|
CA2826114A1
(en)
*
|
2011-02-01 |
2012-08-09 |
Fate Therapeutics, Inc. |
Cardiotrophin related molecules for enhanced therapeutics
|
US9480624B2
(en)
|
2011-03-31 |
2016-11-01 |
Amgen Inc. |
Vial adapter and system
|
WO2012138941A1
(en)
|
2011-04-05 |
2012-10-11 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
TR201905991T4
(tr)
|
2011-04-20 |
2019-05-21 |
Amgen Inc |
Oto enjektör aparatı.
|
US9320777B2
(en)
|
2011-05-13 |
2016-04-26 |
Bolder Biotechnology, Inc. |
Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
|
WO2012166622A1
(en)
*
|
2011-05-27 |
2012-12-06 |
Baxter International Inc. |
Therapeutic proteins with increased half-life and methods of preparing same
|
CA2840409A1
(en)
|
2011-06-28 |
2013-01-03 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
LT3045187T
(lt)
|
2011-10-14 |
2019-07-10 |
Amgen Inc. |
Injekcijų įrenginys ir surinkimo būdas
|
EA201700111A1
(ru)
|
2011-10-28 |
2018-02-28 |
Тева Фармасьютикал Австралия Пти Лтд |
Полипептидные конструкции и их применение
|
HUE043552T2
(hu)
|
2012-06-08 |
2019-09-30 |
Sutro Biopharma Inc |
Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
|
CN103509102B
(zh)
*
|
2012-06-15 |
2015-07-22 |
郭怀祖 |
野生型人生长激素突变体
|
EP2863955B1
(en)
|
2012-06-26 |
2016-11-23 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
BR112015004022B1
(pt)
|
2012-08-31 |
2023-04-25 |
Sutro Biopharma, Inc |
Aminoácidos modificados compreendendo um grupo azido
|
GB2507341A
(en)
*
|
2012-10-29 |
2014-04-30 |
Peter Kenny |
Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
|
ES2780395T3
(es)
|
2012-11-21 |
2020-08-25 |
Amgen Inc |
Dispositivo de administración de fármacos
|
WO2014128701A1
(en)
|
2013-02-20 |
2014-08-28 |
Yeda Research And Development Co. Ltd. |
Interferon treatment targeting mutant p53 expressing cells
|
US20160017017A1
(en)
|
2013-03-11 |
2016-01-21 |
Novo Nordisk Healthcare Ag |
Growth Hormone Compounds
|
BR112015022123B1
(pt)
|
2013-03-15 |
2022-08-09 |
Intrinsic Lifesciences, Llc |
Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
|
WO2014145718A2
(en)
|
2013-03-15 |
2014-09-18 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
TWI639453B
(zh)
|
2013-03-15 |
2018-11-01 |
美商安美基公司 |
用於注射器之匣盒
|
ES2973257T3
(es)
|
2013-03-15 |
2024-06-19 |
Amgen Inc |
Casete de fármaco, autoinyector y sistema de autoinyector
|
IL292270B2
(en)
|
2013-03-22 |
2024-04-01 |
Amgen Inc |
Injector and assembly method
|
US11045523B2
(en)
|
2013-04-05 |
2021-06-29 |
Novo Nordisk Healthcare Ag |
Formulation of growth hormone albumin-binder conjugate
|
RU2679889C2
(ru)
|
2013-04-18 |
2019-02-14 |
Армо Байосайенсиз, Инк. |
Способы применения интерлейкина-10 для лечения заболеваний и расстройств
|
EP2989240A4
(en)
*
|
2013-04-24 |
2016-10-19 |
Armo Biosciences Inc |
INTERLEUKIN-10 COMPOSITIONS AND USES THEREOF
|
AU2014257906A1
(en)
*
|
2013-04-26 |
2015-12-10 |
Philogen S.P.A. |
IL4 conjugated to antibodies against extracellular matrix components
|
UA113129C2
(xx)
|
2013-04-29 |
2016-12-12 |
|
ЗЛИТА КОНСТРУКЦІЯ АНТИТІЛО ПРОТИ CD38 З ОСЛАБЛЕНИМ ІНТЕРФЕРОНОМ АЛЬФА-2b
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
WO2015000585A1
(en)
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
CA2920666A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
AU2014311432A1
(en)
|
2013-08-30 |
2016-03-03 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
WO2015036553A1
(en)
|
2013-09-16 |
2015-03-19 |
Novo Nordisk Health Care Ag |
Thiol functionalized polymers
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3421066B1
(en)
|
2013-10-24 |
2021-03-03 |
Amgen Inc. |
Injector and method of assembly
|
EP3957345A1
(en)
|
2013-10-24 |
2022-02-23 |
Amgen, Inc |
Drug delivery system with temperature-sensitive control
|
JP6660297B2
(ja)
|
2013-11-11 |
2020-03-11 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
疾患及び障害を処置するためのインターロイキン−10の使用方法
|
US9959384B2
(en)
|
2013-12-10 |
2018-05-01 |
Bioniz, Llc |
Methods of developing selective peptide antagonists
|
EP3079722B1
(en)
|
2013-12-13 |
2021-03-24 |
Novo Nordisk Health Care AG |
Method for thioether conjugation of proteins
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
MA39934A
(fr)
|
2014-05-01 |
2017-03-08 |
Hoffmann La Roche |
Variants d'anticorps anti-facteur d et leurs utilisations
|
CA3193070A1
(en)
|
2014-05-07 |
2015-11-12 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
CN106573072A
(zh)
|
2014-06-02 |
2017-04-19 |
阿尔莫生物科技股份有限公司 |
降低血清胆固醇的方法
|
JP6808494B2
(ja)
|
2014-06-03 |
2021-01-06 |
アムジエン・インコーポレーテツド |
薬物送達システム及び使用方法
|
US10519209B2
(en)
*
|
2014-07-14 |
2019-12-31 |
Gennova Biopharmaceuticals Limited |
Process for purification of rHu-GCSF
|
US10323088B2
(en)
|
2014-09-22 |
2019-06-18 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
MX2021014323A
(es)
|
2014-10-14 |
2023-02-02 |
Amgen Inc |
Dispositivo de inyección de fármaco con indicadores visuales y audibles.
|
EP3206713A4
(en)
|
2014-10-14 |
2018-06-27 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
MX2017004983A
(es)
|
2014-10-22 |
2017-11-13 |
Armo Biosciences Inc |
Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
|
CN107108710B
(zh)
|
2014-10-24 |
2022-02-15 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
JP6730271B2
(ja)
|
2014-10-29 |
2020-07-29 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
インターフェロンα2Bバリアント
|
JP6716566B2
(ja)
|
2014-12-19 |
2020-07-01 |
アムジエン・インコーポレーテツド |
近接センサ付き薬物送達装置
|
EP3689394A1
(en)
|
2014-12-19 |
2020-08-05 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
AU2016220141B2
(en)
|
2015-02-17 |
2018-07-12 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
EP3261690B1
(en)
|
2015-02-27 |
2021-12-15 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
WO2016191587A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
WO2016193380A1
(en)
|
2015-06-02 |
2016-12-08 |
Novo Nordisk A/S |
Insulins with polar recombinant extensions
|
US10874717B2
(en)
|
2015-07-07 |
2020-12-29 |
Burr Oak Therapeutics LLC |
Pegylated growth hormone antagonists
|
AU2016312510A1
(en)
|
2015-08-25 |
2018-03-08 |
Armo Biosciences, Inc. |
Methods of using Interleukin-10 for treating diseases and disorders
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
US11229683B2
(en)
|
2015-09-18 |
2022-01-25 |
Bolder Biotechnology, Inc. |
Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
|
MA43348A
(fr)
|
2015-10-01 |
2018-08-08 |
Novo Nordisk As |
Conjugués de protéines
|
PT3359556T
(pt)
|
2015-10-09 |
2021-08-30 |
Bioniz Llc |
Modulação da atividade de citocinas gama-c
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
EP3368090A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody variant conjugates and uses thereof
|
CA3002573A1
(en)
|
2015-11-03 |
2017-05-11 |
Ambrx, Inc. |
Anti-cd3 antibodies and their uses
|
ES2755717T3
(es)
|
2015-12-09 |
2020-04-23 |
Amgen Inc |
Autoinyector con tapa de señalización
|
WO2017120178A1
(en)
|
2016-01-06 |
2017-07-13 |
Amgen Inc. |
Auto-injector with signaling electronics
|
DK3429663T3
(da)
|
2016-03-15 |
2020-09-28 |
Amgen Inc |
Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
|
WO2017189432A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
CA3018426A1
(en)
|
2016-05-13 |
2017-11-16 |
Amgen Inc. |
Vial sleeve assembly
|
US11238150B2
(en)
|
2016-05-16 |
2022-02-01 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
EP3465124A1
(en)
|
2016-06-03 |
2019-04-10 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
TW201808987A
(zh)
*
|
2016-06-08 |
2018-03-16 |
健生生物科技公司 |
Gm-csf變體及使用方法
|
WO2018004842A1
(en)
|
2016-07-01 |
2018-01-04 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
US20190328965A1
(en)
|
2016-08-17 |
2019-10-31 |
Amgen Inc. |
Drug delivery device with placement detection
|
EP3532127A1
(en)
|
2016-10-25 |
2019-09-04 |
Amgen Inc. |
On-body injector
|
EP3570917A1
(en)
|
2017-01-17 |
2019-11-27 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
US10266578B2
(en)
|
2017-02-08 |
2019-04-23 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
AU2018220538B2
(en)
|
2017-02-17 |
2023-12-14 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
MX2019009755A
(es)
|
2017-02-17 |
2019-10-07 |
Amgen Inc |
Mecanismo de insercion para dispositivo de suministro de farmacos.
|
MX2019010544A
(es)
|
2017-03-06 |
2019-10-21 |
Amgen Inc |
Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
|
US11571511B2
(en)
|
2017-03-07 |
2023-02-07 |
Amgen Inc. |
Insertion mechanism and method of inserting a needle of a drug delivery device
|
WO2018165499A1
(en)
|
2017-03-09 |
2018-09-13 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
EP3570871B1
(en)
|
2017-03-20 |
2020-11-18 |
H. Hoffnabb-La Roche Ag |
Method for in vitro glycoengineering of an erythropoiesis stimulating protein
|
ES2959935T3
(es)
|
2017-03-28 |
2024-02-29 |
Amgen Inc |
Sistema y método de vástago de émbolo y conjunto de jeringa
|
MA49339A
(fr)
|
2017-04-05 |
2020-02-12 |
Novo Nordisk As |
Conjugués insuline-fc à extension oligomère
|
AU2018282077B2
(en)
|
2017-06-08 |
2023-11-23 |
Amgen Inc. |
Torque driven drug delivery device
|
EP3634539A1
(en)
|
2017-06-08 |
2020-04-15 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
MA49447A
(fr)
|
2017-06-22 |
2020-04-29 |
Amgen Inc |
Réduction des impacts/chocs d'activation d'un dispositif
|
WO2018237225A1
(en)
|
2017-06-23 |
2018-12-27 |
Amgen Inc. |
ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
|
EP3651832B1
(en)
|
2017-07-14 |
2023-12-13 |
Amgen Inc. |
Needle insertion-retraction system having dual torsion spring system
|
WO2019018169A1
(en)
|
2017-07-21 |
2019-01-24 |
Amgen Inc. |
PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
|
JP7242562B2
(ja)
|
2017-07-25 |
2023-03-20 |
アムジエン・インコーポレーテツド |
容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
|
EP3658203B1
(en)
|
2017-07-25 |
2022-08-31 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
US20200164155A1
(en)
|
2017-08-09 |
2020-05-28 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
MA49897A
(fr)
|
2017-08-18 |
2020-06-24 |
Amgen Inc |
Injecteur sur-corps avec patch adhésif stérile
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
WO2019051073A1
(en)
|
2017-09-08 |
2019-03-14 |
Bristol-Myers Squibb Company |
MODIFIED FIBROBLAST GROWTH FACTOR 21 (FGF-21) FOR USE IN NON-ALCOHOLIC STÉATOHÉPATITE (NASH) TREATMENT METHODS
|
US11759565B2
(en)
|
2017-10-04 |
2023-09-19 |
Amgen Inc. |
Flow adapter for drug delivery device
|
IL272636B1
(en)
|
2017-10-06 |
2024-06-01 |
Amgen Inc |
Drug delivery device with combination assembly and related assembly method
|
US11464903B2
(en)
|
2017-10-09 |
2022-10-11 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
WO2019090079A1
(en)
|
2017-11-03 |
2019-05-09 |
Amgen Inc. |
System and approaches for sterilizing a drug delivery device
|
US20200261648A1
(en)
|
2017-11-06 |
2020-08-20 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
MA50569A
(fr)
|
2017-11-06 |
2020-09-16 |
Amgen Inc |
Ensembles de remplissage-finition et procédés associés
|
CN116832271A
(zh)
|
2017-11-10 |
2023-10-03 |
安进公司 |
用于药物递送装置的柱塞
|
MA50904A
(fr)
|
2017-11-16 |
2020-09-23 |
Amgen Inc |
Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
|
AU2018368338B2
(en)
|
2017-11-16 |
2024-07-25 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
WO2019131964A1
(ja)
*
|
2017-12-27 |
2019-07-04 |
協和発酵キリン株式会社 |
Il-2改変体
|
WO2019130344A1
(en)
*
|
2017-12-27 |
2019-07-04 |
Council Of Scientific And Industrial Research |
A polypeptide exhibiting granulocyte-colony stimulating factor activity
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
CN114903978A
(zh)
|
2018-07-03 |
2022-08-16 |
百时美施贵宝公司 |
Fgf-21配制品
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
US20210260279A1
(en)
|
2018-07-24 |
2021-08-26 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
CN112469454B
(zh)
|
2018-07-24 |
2024-01-26 |
安进公司 |
用于施用药物的输送装置
|
US20210128844A1
(en)
|
2018-07-24 |
2021-05-06 |
Amgen Inc. |
Delivery devices for administering drugs
|
EP3829692A1
(en)
|
2018-07-31 |
2021-06-09 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
JP2021535140A
(ja)
|
2018-08-28 |
2021-12-16 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
抗cd3抗体葉酸生物複合体およびその使用
|
CA3111576A1
(en)
|
2018-09-11 |
2020-03-19 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
US20210346601A1
(en)
|
2018-09-24 |
2021-11-11 |
Amgen Inc. |
Interventional dosing systems and methods
|
AU2019350660A1
(en)
|
2018-09-28 |
2021-03-18 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
SG11202103236YA
(en)
|
2018-10-02 |
2021-04-29 |
Amgen Inc |
Injection systems for drug delivery with internal force transmission
|
TWI824026B
(zh)
|
2018-10-05 |
2023-12-01 |
美商安進公司 |
具有劑量指示器之藥物遞送裝置
|
SG11202103800RA
(en)
|
2018-10-15 |
2021-05-28 |
Amgen Inc |
Drug delivery device having damping mechanism
|
MX2021002791A
(es)
|
2018-10-15 |
2021-05-12 |
Amgen Inc |
Proceso de ensamblaje de plataforma para un dispositivo de administracion de farmacos.
|
US20220009986A1
(en)
|
2018-10-19 |
2022-01-13 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
US11213620B2
(en)
|
2018-11-01 |
2022-01-04 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
CA3113076A1
(en)
|
2018-11-01 |
2020-05-07 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
WO2020096958A1
(en)
|
2018-11-05 |
2020-05-14 |
Bristol-Myers Squibb Company |
Method for purifying pegylated protein
|
CN111378026A
(zh)
*
|
2018-12-27 |
2020-07-07 |
天津键凯科技有限公司 |
一种制备结合位点可控的peg化生物分子的方法
|
CA3128081A1
(en)
|
2019-02-12 |
2020-08-20 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
AU2020258384A1
(en)
|
2019-04-15 |
2021-11-04 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
|
MX2021012557A
(es)
|
2019-04-24 |
2021-11-12 |
Amgen Inc |
Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
|
CN113874075A
(zh)
|
2019-05-03 |
2021-12-31 |
比奥尼斯有限责任公司 |
调节γC-细胞因子信号传导对于治疗脱发和脱发相关病症的影响
|
MX2022002149A
(es)
|
2019-08-23 |
2022-03-17 |
Amgen Inc |
Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
AU2021233909A1
(en)
|
2020-03-11 |
2022-09-29 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
EP4126949A1
(en)
|
2020-03-24 |
2023-02-08 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
US20220033804A1
(en)
*
|
2020-07-30 |
2022-02-03 |
Georgia Tech Research Corporation |
Methods and Compositions for Enhancement of Stem Cell-based Immunomodulation and Tissue Repair
|
US20230302150A1
(en)
|
2020-08-20 |
2023-09-28 |
Ambrx, Inc. |
Antibody-tlr agonist conjugates, methods and uses thereof
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
WO2022212899A1
(en)
|
2021-04-03 |
2022-10-06 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|
CA3217207A1
(en)
|
2021-05-21 |
2022-11-24 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
CN114920819A
(zh)
*
|
2022-06-16 |
2022-08-19 |
修正生物医药(杭州)研究院有限公司 |
重组人生长激素突变体、其聚乙二醇衍生物、聚乙二醇衍生物的制备方法及其药物用途
|
WO2024026224A1
(en)
|
2022-07-29 |
2024-02-01 |
University Of Rochester |
Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone
|
WO2024094457A1
(en)
|
2022-11-02 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Method for producing glycoprotein compositions
|